Phelebothomy in polycystic ovarian syndrome (PCOS)

Comparison of phlebothomy and Cyproterone compound in insulin resistance, antimullerian hormone(AMH) and prostatic specific antigen(PSA) in polycystic ovarian syndrome patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013080514277N1

Enrollment

120

Registered

2014-06-16

Start date

2014-06-22

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrom. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group (Phlebotomy group): Patients undergo venesection of 450 ml of whole blood and are advised not to use any hormonal or iron- containing medications. Intervention 2: Co

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: PCOS patients 18-45 years old Hgb more than 12 ferritine more than 20 free of diabetes melitus free of heart disease free of hypertension free of cancer free of thyroid problem

Exclusion criteria

Exclusion criteria: pregnancy ?Diabetes Cardiovascular disease Hypertension Thyroid disease cancer

Design outcomes

Primary

Measure	Time frame
Insulin resistance with Homeostatic Model Assessment (HOMA-IR). Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Laboratory.;Anti mullerian hormone. Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Laboratory assessment.;Prostate-Specific Antigen. Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Laboratory.	—

Measure

Time frame

Insulin resistance with Homeostatic Model Assessment (HOMA-IR). Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Laboratory.;Anti mullerian hormone. Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Laboratory assessment.;Prostate-Specific Antigen. Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Laboratory.

—

Secondary

Measure	Time frame
Hirsutism Score. Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: clinical.;Menstural irregularity. Timepoint: Before intervention and immediately after intervention (3 month). Method of measurement: Questionair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Navid Saadat

Research Institute for Endocrine Sciences

saadat@endocrine.ac.ir+98 21 2243 2500

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 20, 2026